April 15, 2021 -- Inovio has announced promising results from a study focusing on the human immune responses induced by its DNA vaccine candidate for COVID-19, INO-4800.
Results showed that INO-4800 induced a robust T-cell response against all spike protein variants tested, which may be a key in providing protection against SARS-CoV-2 variants. In addition, the vaccine provides similar levels of neutralizing activity against both the U.K. and Brazilian variants of SARS-CoV-2 as those against the original strain.
More than 3,000 patients are receiving Inovio's investigational DNA medicines in more than 7,000 applications across a range of clinical trials. This latest study has been submitted for peer review and can be viewed on bioRxiv.
Copyright © 2021 scienceboard.net